Insights provides context and perspective about key pharmacy trends and issues

Drug Pipeline
A Q2 2022 Look at Projected Gene Therapies and FDA Approval Timelines More
Briefing
Drug Pipeline
New Gene Therapies for Sickle Cell Disease, Hemophilia on the Horizon More
Briefing
Drug Pipeline
As more treatments for inflammatory bowel disease are approved, payors can counter cost increases with comprehensive utilization management. More
Briefing
Drug Pipeline
2022 Marketplace Outlook: Expanding Therapies, Indications and Implications for Payors More
Briefing
Drug Pipeline
Breakthrough Therapies and New Biologics Feature in the Gene Therapy Pipeline More
Briefing
Speciality Pharmacy Pipeline Drugs to Watch | Q4 2021 - Q1 2022
Drug Pipeline
Key drugs to watch for in the specialty pharmacy pipeline Q4 2021 - Q1 2022 More
Specialty Report
Drug Pipeline
... More
Briefing
Drug Pipeline
The gene therapy pipeline report highlights what payors can expect for a variety of conditions. More
Briefing
Drug Pipeline
Biosimilars help to increase market competition. Balancing the use of biosimilars and biologics with strategic formulary decisions deliver lower costs. More
Briefing
Speciality Pharmacy Pipeline Drugs to Watch | Q3 - Q4 2021
Drug Pipeline
Key drugs to watch for in the specialty pharmacy pipeline Q3 - Q4 2021 More
Specialty Report